Valuation: Noxopharm Limited

Market Cap 26.73M 19.12M 16.39M 15.35M 14.03M 26.47M 1.82B 181M 70.51M 920M 71.8M 70.24M 3.05B P/E 2024
-5.39x
P/E 2025 -3.23x
Enterprise Value 27.65M 19.78M 16.95M 15.89M 14.51M 27.38M 1.89B 187M 72.95M 952M 74.29M 72.67M 3.15B EV / Sales 2024
7.07x
EV / Sales 2025 5.92x
Free-Float
71.75%
Yield 2024 *
-
Yield 2025 -
1 day-3.16%
1 week+21.05%
Current month+12.20%
1 month+12.20%
3 months+6.98%
6 months+41.54%
Current year-1.08%
1 week 0.08
Extreme 0.076
0.1
1 month 0.08
Extreme 0.076
0.1
Current year 0.05
Extreme 0.051
0.11
1 year 0.05
Extreme 0.051
0.12
3 years 0.03
Extreme 0.033
0.16
5 years 0.03
Extreme 0.033
0.6
10 years 0.03
Extreme 0.033
1.8
Manager TitleAgeSince
Chief Executive Officer - 2026-04-14
Director of Finance/CFO - 2019-02-28
Corporate Officer/Principal - 2017-12-31
Director TitleAgeSince
Chairman 70 2016-03-14
Director/Board Member - 2020-03-25
Chairman 71 2020-09-08
Date Insider Type Main position Quantity % Market Cap.
9/20/23 Buy

Chairman

880 0.0003%
9/17/23 Buy

Chairman

253,001 0.0866%
7/3/23 Buy

Chairman

135,281 0.0463%
Change 5-day change 1-year change 3-year change Capi.($)
-3.16%+21.05%-16.36%+162.86% 20.88M
-0.24%+2.21%+2.39%+24.50% 51.65B
-0.09%-2.14%+492.60%+537.84% 45.31B
-0.32%+8.08%+37.97%+18.45% 42.7B
+1.18%+1.96%+21.95%+89.69% 42.79B
-2.27%-3.02%+14.22%+51.50% 32.87B
-0.96%+4.03%+31.55%+136.34% 17.14B
+0.41%+1.66% - - 16.61B
+0.51%+5.43%+13.67%+31.53% 15.01B
-0.31%+6.61%+81.37%+48.53% 14.21B
Average -0.54%+4.55%+75.48%+122.36% 27.83B
Weighted average by Cap. -0.24%+2.74%+104.59%+135.48%

Financials

2024 2025
Net sales 2.4M 1.72M 1.47M 1.38M 1.26M 2.38M 164M 16.26M 6.33M 82.59M 6.45M 6.31M 274M 2.82M 2.02M 1.73M 1.62M 1.48M 2.79M 192M 19.11M 7.44M 97.07M 7.58M 7.41M 321M
Net income -3.58M -2.56M -2.19M -2.06M -1.88M -3.54M -244M -24.24M -9.44M -123M -9.61M -9.4M -408M -4.88M -3.49M -2.99M -2.81M -2.56M -4.84M -333M -33.09M -12.88M -168M -13.12M -12.83M -557M
Net Debt -2.32M -1.66M -1.42M -1.33M -1.22M -2.3M -158M -15.72M -6.12M -79.83M -6.23M -6.1M -264M 925K 662K 567K 531K 485K 916K 63.09M 6.27M 2.44M 31.83M 2.48M 2.43M 105M
Logo Noxopharm Limited
Noxopharm Limited is a clinical-stage biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA drug enhancement, and oncology). Chroma is a technology platform, which is focused on development of drug candidates based on a scaffold structure known as functionalized benzopyrans. Sofra technology platform comprises a novel class of drugs targeting inflammatory and autoimmune diseases based on oligonucleotides, the building blocks of DNA, with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-SKN is a novel drug candidate for autoimmune diseases that targets an inflammatory sensor called TLR7.
Employees
-
Date Price Change Volume
26-08-26 A$0.0920 -3.16% 20,491
26-08-25 A$0.0950 +3.26% 63,812
26-08-24 A$0.0920 -2.13% 117,340
26-08-21 A$0.0940 +11.90% 148,542
26-08-20 A$0.0840 +10.53% 446,863